GlassScriptPhysician profile
Ahmed Omar
NPI 1588193775
$1,246.72
in general payments reported to CMS, 2019-2025
17 companies · $249 in 2025
The $249 reported for 2025 was more than what 80% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.64 · 2022: $375 · 2023: $273 · 2024: $335 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $857.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $343.45 | 2022-2024 | Farxiga, Lokelma, Andexxa |
| E.R. Squibb & Sons, L.L.C. | $269.41 | 2022-2025 | Eliquis, Camzyos |
| Pfizer INC. | $114.02 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $81.31 | 2024 | Surgical Misc |
| Gilead Sciences, INC. | $59.08 | 2021-2022 | |
| Ceribell, INC. | $55.60 | 2023-2025 | Pocket Eeg Device, Ceribell Rapid Response Eeg |
| Novo Nordisk INC | $54.11 | 2023-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $50.35 | 2022-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $47.44 | 2022 | |
| Mallinckrodt Hospital Products INC. | $31.67 | 2025 | Terlivaz |
| Otsuka America Pharmaceutical, INC. | $26.93 | 2025 | Jynarque |
| Kestra Medical Technology Services, INC. | $23.08 | 2025 | Assure Wcd |
| Eisai INC. | $21.77 | 2022 | |
| Merck Sharp & Dohme LLC | $21.18 | 2023 | Dificid, Zerbaxa |
| Janssen Scientific Affairs, LLC | $18.85 | 2023 | Xarelto |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $14.84 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $13.63 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Omar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.